PAULA SANDRIN-GARCIA

Dr. PAULA SANDRIN-GARCIA

Genetics, Federal University of Pernambuco, Recife, Pernambuco, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
COCamila Barbosa Lyra Oliveira
Camila Barbosa Lyra Oliveira
CLCamilla de Lima
Camilla de Lima
GVGisele Vajgel
Gisele Vajgel
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Lupus nephritis (LN) is the most frequent and severe of systemic lupus erythematosus (SLE) clinical manifestations and contributes to the increase of morbidity and mortality of patients due to chronic kidney disease. The NLRP3 (NLR pyrin domain containing 3) is a member of the NLR (NOD-like receptors), and its activation results in the production of pro-inflammatory cytokines, which can contribute to the pathogenesis of LN. In this review manuscript, we approach the relation between the NLRP3 inflammasome, SLE, and LN, highlighting the influence of genetic susceptibility of NLRP3 polymorphisms in the disease; the main functional studies using cellular and animal models of NLRP3 activation; and finally, some mechanisms of NLRP3 inhibition for the development of possible therapeutic drugs for LN.

14 August 2013 in Lupus
Verified
Journal Article
Closed access
PDF file
JSJ de Azevêdo Silva
J de Azevêdo Silva
KFK Monteiro Fernandes
K Monteiro Fernandes
JPJa Trés Pancotto
Ja Trés Pancotto
TFT Sotero Fragoso
T Sotero Fragoso
EDEa Donadi
Ea Donadi
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Systemic lupus erythematosus (SLE) is an autoimmune disorder with heterogeneous clinical manifestations and target tissue damage. Currently, several genes have been associated with SLE susceptibility, including vitamin D receptor (VDR), which is a mediator of immune responses through the action of vitamin D. Polymorphisms in the VDR gene can impair the vitamin D (D3) function role, and since SLE patients show deficient D3 blood levels, it leads to a possible connection to the disease’s onset. In our study we searched for an association between VDR polymorphisms and risk of developing SLE, as well as the disease’s clinical manifestations. We enrolled 158 SLE patients and 190 Southeast Brazilian healthy controls, genotyped for five Tag single nucleotide polymorphisms (SNPs), covering most of the VDR gene region. We found an association between VDR SNPs and SLE for the following clinical manifestations: rs11168268 and cutaneous alterations ( p = 0.036), rs3890733 ( p = 0.003) rs3890733 and arthritis ( p = 0.001), rs2248098 and immunological alterations ( p = 0.040), rs4760648 and antibody anti-dsDNA ( p = 0.036). No association was reported between VDR polymorphisms and SLE susceptibility.

2 December 2022 in Genes
Verified
Journal Article
Open access
PDF file
WGWerbson Lima Guaraná
Werbson Lima Guaraná
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
ABAlexandre Domingues Barbosa
Alexandre Domingues Barbosa
Sergio CrovellaSergio Crovella
Sergio Crovella
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
The immune system plays a critical role in bone homeostasis and, consequently, in the pathophysiology of postmenopausal osteoporosis (OP) since estrogen deficiency induces the inflammasome and increases production of pro-inflammatory cytokines, such as IL-1β and IL-18. NLRP3 inflammasome complex genes have been related with bone homeostasis in cellular and animal models. Here, we performed an association study evaluating SNVs (single-nucleotide variants) in inflammasome NLRP3 pathway genes (NLRP3, CARD8, CASP1, IL-18, and IL-1β) to assess whether variants in these genes could be related to susceptibility to primary OP in postmenopausal women. Methods: We genotyped 196 postmenopausal OP patients and 103 healthy controls using SNV-specific Taqman® probes. Data and statistical analyses were performed using the SNPstats and GraphPad Prism 8 software. Results: We showed an association between NLRP3 rs35829419 CA genotype and lower bone mineral density (BMD) mean at the lumbar spine (p = 0.001); we also observed an association between IL-1β rs16944 AA genotype and higher BMD mean at the total hip (p = 0.009). The IL-1β rs16944 GG was associated with lower alkaline phosphatase levels (ALP) (p = 0.009), and the IL-18 rs1946519 AA was associated with lower vitamin D levels (p = 0.018). Additionally, OP patients presented deficient vitamin D and parathyroid hormone (PTH). Conclusions: The NLRP3 inflammasome complex SNVs were associated with OP severity, possibly indicating these genes’ participation in bone metabolism and its dysregulation.

27 November 2008
Verified
Journal Article
Closed access
HFH T Fuzii
H T Fuzii
GYG T Yoshikawa
G T Yoshikawa
CJC M Junta
C M Junta
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
AFA L Fachin
A L Fachin
LAL E C Andrade
L E C Andrade

12 January 2014 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JSJaqueline De Azevêdo Silva
Jaqueline De Azevêdo Silva
JPJoão Alexandre Trés Pancotto
João Alexandre Trés Pancotto
EDEduardo A. Donadi
Eduardo A. Donadi
Sergio CrovellaSergio Crovella
Sergio Crovella
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA

Verified
Journal Article
Open access
PDF file
WGWerbson Lima Guaraná
Werbson Lima Guaraná
CLCamilla Albertina Dantas de Lima
Camilla Albertina Dantas de Lima
ABAlexandre Domingues Barbosa
Alexandre Domingues Barbosa
Sergio CrovellaSergio Crovella
Sergio Crovella
PSPAULA SANDRIN-GARCIA
PAULA SANDRIN-GARCIA
Aminobisphosphonates (NBPs) are the first-choice medication for osteoporosis (OP); NBP treatment aims at increasing bone mineral density (BMD) by inhibiting the activity of farnesyl diphosphate synthase (FDPS) enzyme in osteoclasts. Despite its efficacy, inadequate response to the drug and side effects have been reported. The A allele of the rs2297480 (A > C) SNP, found in the regulatory region of the FDPS gene, is associated with reduced gene transcription. This study evaluates the FDPS variant rs2297480 (A > C) association with OP patients’ response to alendronate sodium treatment. A total of 304 OP patients and 112 controls were enrolled; patients treated with alendronate sodium for two years were classified, according to BMD variations at specific regions (lumbar spine (L1-L4), femoral neck (FN) and total hip (TH), as responders (OP-R) (n = 20) and non-responders (OP-NR) (n = 40). We observed an association of CC genotype with treatment failure (p = 0.045), followed by a BMD decrease in the regions L1-L4 (CC = −2.21% ± 2.56; p = 0.026) and TH (CC = −2.06% ± 1.84; p = 0.015) after two years of alendronate sodium treatment. Relative expression of the FDPS gene was also evaluated in OP-R and OP-NR patients. Higher expression of the FDPS gene was also observed in OP-NR group (FC = 1.84 ± 0.77; p = 0.006) when compared to OP-R. In conclusion, the influence observed of FDPS expression and the rs2897480 variant on alendronate treatment highlights the importance of a genetic approach to improve the efficacy of treatment for primary osteoporosis.